Who we are
We are a clinical-stage oncology company focused on identifying innovative technologies and advancing truly breakthrough medicines for the treatment of cancer.
Led by an experienced team in translational science and drug development, we acquire licenses for high potential development candidates, we invest in partners with transformative technology platforms, and we build our own internal programs.
Our Company (Onward Therapeutics, Inc.) is headquartered in Taipei, Taiwan, and has a subsidiary (Onward Therapeutics SA) in Lausanne, Switzerland, and two sub-subsidiaries (Onward Therapeutics France including an R&D laboratory, and Emercell) in Paris and Montpellier, France.
Vision
Innovate in oncology drug development through efficient, sustainable, and adaptive approaches.
Mission
Deliver effective treatments for hard-to-treat and resistant cancers
• Biologics have profoundly transformed cancer therapy by targeting cancer cells more precisely and by harnessing the immune system.
• Over the past decade, numerous Immune Checkpoint Inhibitors (ICIs), T-Cell Engagers (TCE), CAR-T cell therapies, and Antibody-Drug Conjugates (ADCs) have received approval, marking significant milestones in cancer treatment.
• Nevertheless, the proportion of patients who respond favorably is still quite modest, due in particular to the acquisition of tumor resistance mechanisms.
Our approach
• Focused on the mechanisms of tumor resistance and high-impact targets
• Modality agnostic
• First/best-in-class candidates with clear differentiation
• Addressing high-need, underserved indications and patient populations
• Accelerate development toward clinical proof-of-concept
